Clinical Edge Journal Scan

Preoperative D-dimer-to-albumin ratio: A biomarker for long-term prognosis in gastric cancer


 

Key clinical point: Preoperative D-dimer-to-albumin ratio (DAR) serves as an independent predictive marker for long-term prognosis in patients with gastric cancer.

Major finding: The low-DAR vs high-DAR group had significantly higher overall survival (OS; 63.8% vs 44.2%; P < .001) and recurrence-free survival (RFS; 62.4% vs 46.6%; P < .001) rates. The preoperative DAR was an independent risk factor for OS (training cohort: adjusted hazard ratio [aHR] 1.47; P < .001; testing cohort: aHR 1.50; P = .014) and RFS (training cohort: aHR 1.43; P < .001; testing cohort: aHR 1.59; P = .006).

Study details: This retrospective study included 1766 patients with gastric cancer who underwent gastrectomy (training cohort n = 1236; testing cohort n = 530) and were categorized into the high-DAR (>0.0145) or low-DAR (≤0.0145) group.

Disclosures: No information on the source of funding was provided. The authors declared no conflicts of interest.

Source: Lin GS et al. Value of the preoperative D-dimer to albumin ratio for survival and recurrence patterns in gastric cancer. Ann Surg Oncol. 2022 (Oct 25). Doi: 10.1245/s10434-022-12625-7

Recommended Reading

Metastatic microsatellite-stable CRC: CXD101 and nivolumab combo shows promise in phase 2
MDedge Hematology and Oncology
Impact of synchronous ovarian metastases on 3-year overall survival in CRC
MDedge Hematology and Oncology
High risk for incident cardiovascular disease in patients with high-risk stage II-III CRC
MDedge Hematology and Oncology
CRC: Severe inflammatory response in early postoperative period increases risk for recurrence
MDedge Hematology and Oncology
Excellent prognostic ability of neutrophil-to-lymphocyte ratio in CRC liver metastasis
MDedge Hematology and Oncology
mCRC: Triplet+bevacizumab offers survival advantage even in patients with bone metastasis
MDedge Hematology and Oncology
Comparative analysis of total neoadjuvant therapy vs standard therapy in LARC
MDedge Hematology and Oncology
ctDNA detection following curative surgery for colorectal cancer predicts poor prognosis
MDedge Hematology and Oncology
Bemarituzumab shows promising efficacy in patients with FGFR2b-selected gastric cancer
MDedge Hematology and Oncology
Gastric ulcer increases the risk for gastric cancer
MDedge Hematology and Oncology